| Willingness to pay for drug abuse treatment: results from a contingent valuation study in Taiwan CH Tang, JT Liu, CW Chang, WY Chang Health Policy 82 (2), 251-262, 2007 | 42 | 2007 |
| A cost-effectiveness analysis of nintedanib in idiopathic pulmonary fibrosis in the UK C Rinciog, M Watkins, S Chang, TM Maher, C LeReun, D Esser, ... Pharmacoeconomics 35, 479-491, 2017 | 41 | 2017 |
| Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes L Sawyer, JM Azorin, S Chang, C Rinciog, A Guiraud-Diawara, C Marre, ... Journal of medical economics 17 (7), 508-519, 2014 | 21 | 2014 |
| Cannabis-based medicinal products: summary of NICE guidance S Chang-Douglass, C Mulvihill, S Pilling Bmj 369, 2020 | 20 | 2020 |
| Network meta-analysis of tofacitinib, biologic disease-modifying antirheumatic drugs, and apremilast for the treatment of psoriatic arthritis DD Gladman, AM Orbai, J Gomez-Reino, S Chang-Douglass, E Leoncini, ... Current Therapeutic Research 93, 100601, 2020 | 13 | 2020 |
| Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States G Bungey, S Chang-Douglass, MA Hsu, JC Cappelleri, P Young, ... Journal of Managed Care & Specialty Pharmacy 26 (8), 1027-1038, 2020 | 3 | 2020 |
| THU0300 Network meta-analysis of tofacitinib vs bdmards or apremilast for the treatment of tnf inhibitor-naÏve patients with psoriatic arthritis DD Gladman, AM Orbai, J Gomez-Reino, S Chang-Douglass, E Leoncini, ... Annals of the Rheumatic Diseases 77 (Suppl 2), 368-369, 2018 | 2 | 2018 |
| The cost-effectiveness of detecting arrhythmia with implantable loop recorders in the United state of America J Rogers, S Chang, ME Quiroz, T Madden, A Diamantopoulos, ... Value in Health 17 (3), A116, 2014 | 2 | 2014 |
| Nintedanib cost-effectiveness in idiopathic pulmonary fibrosis in the UK C Rinciog, M Watkins, S Chang, T Maher, C LeReun, D Esser, ... Value in Health 19 (7), A553, 2016 | 1 | 2016 |
| Mabthera®(Rituximab) for the Treatment of Severe Granulomatosis With Polyangiitis (Gpa) and Microscopic Polyangiitis (Mpa)–A Cost-Utility Model for the United Kingdom D Harland, B Naisbett-Groet, S Chang, DK Sungher, L Sawyer, ... Value in Health 17 (7), A382, 2014 | 1 | 2014 |
| Tocilizumab in polyarticular juvenile idiopathic arthritis–a cost-utility model for the United Kingdom S Chang, L Sawyer, F Dejonckheere, LW van Suijlekom-Smit, J Anink, ... Value in Health 16 (7), A564, 2013 | 1 | 2013 |
| HTA186 Accelerating Access to Medical Technologies: An Overview of the NICE Early Value Assessment Pilot Project in the UK D So, E Hearne, N Stapleton, S Chang-Douglass Value in Health 26 (12), S355, 2023 | | 2023 |
| EE148 Are General Population Utilities Appropriate to Use as Baselines for Age-Adjustment of Utility Values? S Chang-Douglass, G Bungey Value in Health 26 (12), S78-S79, 2023 | | 2023 |
| MSR7 Multiplicative With Linear Transformation (MLT): An Improvement on the Multiplicative Method for Age and Sex Adjustment of Utilities? G Bungey, S Chang-Douglass, H Dakin Value in Health 25 (12), S351, 2022 | | 2022 |
| MSR36 Modelling of UK General Population Utility: The ALDVMM Approach in Practice S Chang-Douglass, G Bungey, H Dakin Value in Health 25 (12), S356-S357, 2022 | | 2022 |
| PCN171-A COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS ANASTROZOLE AS FIRST-LINE THERAPY FOR OESTROGEN RECEPTOR-POSITIVE LOCALLY ADVANCED AND METASTATIC BREAST CANCER AD Davies, S Chang-Douglass Value in Health 21, S43, 2018 | | 2018 |
| Modeling the Costs and Outcomes Associated with Treatment Sequences, with and without Tofacitinib, for Moderately to Severely Active Psoriatic Arthritis in the US G Bungey, S Chang-Douglass, MA Hsu, JC Cappelleri, P Young, ... ARTHRITIS & RHEUMATOLOGY 70, 2018 | | 2018 |
| Cost-Utility Analysis of Biological Therapies In Psoriasis Using Real World Evidence G Bungey, S Chang-Douglass, R Erickson, J Katiyar Value in Health 20 (9), A556, 2017 | | 2017 |
| Tocilizumab in Methotrexate-Naïve Rheumatoid Arthritis–A Cost-Utility Model for Slovakia S Chang, L Sawyer, F Dejonckheere, L Grichova, A Diamantopoulos Value in Health 18 (7), A648, 2015 | | 2015 |
| EFFICACY OF BIOLOGIC TREATMENTS IN EARLY ACTIVE RHEUMATOID ARTHRITIS: AN INDIRECT COMPARISON L Sawyer, S Chang, A Diamantopoulos, F Dejonckheere RHEUMATOLOGY 54, 80-80, 2015 | | 2015 |
